Clinical trial
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With…
NCT00267917 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00267917 |
|---|---|
| Title | Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique. |
| Official title | A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive, Asthma |
| Intervention type | Device |
| Interventions | Berodual Respimat, Berodual HFA-MDI |
| Enrollment | 13 |
| Start date | Jan 17, 2006 |
| Primary completion | Feb 27, 2006 |
| Completion | Feb 27, 2006 |
| First posted | Dec 22, 2005 |
| Last update posted | Dec 14, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: